Back to Search
Start Over
Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective
- Source :
- Urology. 116
- Publication Year :
- 2017
-
Abstract
- Nonmetastatic castration-resistant prostate cancer (nmCRPC) presents a challenge to urologists as currently there are no Food and Drug Administration-approved therapies. However, there are new imaging modalities, including fluciclovine positron emission tomography-computed tomography and Ga-PSMA (prostate specific membrane antigent) positron emission tomography-computed tomography, which are improving accuracy of diagnosis. With improved imaging, we are better able to target therapy. Today there are 3 ongoing clinical trials studying second-generation antiandrogens in nmCRPC, which hold the promise of a new treatment paradigm. In this article, we will review the new imaging techniques and the rationale behind novel treatment modalities in nmCRPC.
- Subjects :
- Oncology
Male
medicine.medical_specialty
Antineoplastic Agents, Hormonal
Urology
030232 urology & nephrology
Carboxylic Acids
Bone Neoplasms
Castration resistant
Adenocarcinoma
Imaging modalities
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Internal medicine
Nitriles
Phenylthiohydantoin
Biomarkers, Tumor
Medicine
Humans
Multicenter Studies as Topic
Target therapy
Randomized Controlled Trials as Topic
business.industry
Prostate specific membrane
Disease Management
Prostatic Neoplasms
Androgen Antagonists
Prostate-Specific Antigen
medicine.disease
Clinical trial
Clinical Trials, Phase III as Topic
Treatment modality
Drug Resistance, Neoplasm
030220 oncology & carcinogenesis
Benzamides
Pyrazoles
Kallikreins
business
Orchiectomy
Cyclobutanes
Subjects
Details
- ISSN :
- 15279995
- Volume :
- 116
- Database :
- OpenAIRE
- Journal :
- Urology
- Accession number :
- edsair.doi.dedup.....7f3cfa39ac48dcc2ded952cdbfcc394a